Abstract
Preclinical Research Epidermal growth factor receptor (EGFR), a validated target for anticancer drugs, plays a critical role in tumorigenesis and tumor development. A series of p-O-alkyl salicylanilide derivatives were designed and synthesized as novel EGFR inhibitors using a salicylic acid scaffold. A simulated six-membered ring strategy formed through intramolecular hydrogen bonds was employed to mimic the planar quinazoline of the EGFR antagonist, gefitinib. The derived compounds with hydroxyl at the ortho position were more potent than ones with methoxyl group. In particular, compounds 5d and 5b displayed significant EGFR inhibitory (IC50 values = 0.30 and 0.45 μM, respectively) activity as well as potent antiproliferative activity in A431 and HCT-116 tumor cells. These salicylanilides could be considered as promising lead compounds for developing novel EGFR inhibitors.
References
Jul 21, 2001·Journal of Medicinal Chemistry·F MuM Cushman
Nov 1, 2002·Journal of Medicinal Chemistry·Almudena BermejoNuria Cabedo
Dec 28, 2002·Journal of Medicinal Chemistry·Allan WissnerHwei-Ru Tsou
Nov 9, 2005·Bioorganic & Medicinal Chemistry Letters·Wei DengFengming Chu
Mar 18, 2006·Cell Proliferation·J G MahdiI D Bowen
May 8, 2009·Journal of Medicinal Chemistry·Nobuaki SuzukiNaoki Miyata
Dec 25, 2009·Nature·Wenjun ZhouPasi A Jänne
Jan 1, 2009·Advances in Pharmacology·Khosrow Kashfi
Jul 17, 2010·Cardiovascular Therapeutics·Ruitang Deng, Te-Jin Chow
Apr 5, 2012·Nature Reviews. Clinical Oncology·Michael J ThunCarlo Patrono
Jun 19, 2012·Bioorganic & Medicinal Chemistry Letters·Botao XinTao Lu
Nov 3, 2012·Journal of Medicinal Chemistry·Jiao YangSheng-Yong Yang
Oct 15, 2013·European Journal of Medicinal Chemistry·Marc-Antoine BazinPascal Marchand
Jan 1, 2012·Pharmaceuticals·Melania DovizioPaola Patrignani
May 28, 2014·Bioorganic & Medicinal Chemistry Letters·Guangcheng WangLijuan Chen
Dec 3, 2014·European Journal of Medicinal Chemistry·Hongping GaoJie Zhang